AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

6 years ago
Anonymous $qrGo_Xv_Cm

https://www.businesswire.com/news/home/20180607005921/en/

SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2018--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a late-breaker poster presentation describing four case studies of patients suffering from severe Staphylococcus aureus ( S. aureus ) infections, who received treatment with AB-SA01, AmpliPhi’s investigational bacteriophage drug candidate. The presentation will be made at the American Society for Microbiology (ASM) Microbe 2018 annual meeting, being held June 7-11, 2018 in Atlanta. The abstract can be viewed here.

Poster Presentation:

            
Title: AAR LB16 - Bacteriophages as adjuvant therapy for the treatment of severe staphylococcal sepsis Date and time: Friday, June 8, 2018, 11 a.m. - 1 p.m. EDT Session: 048 - FRIDAY - AAR Late-breakers Track: AAR Location: Exhibit and Poster Hall, Building B, Halls B2-B5, Georgia World Congress Center, Atlanta, Georgia Presenter: Dr. Jonathan Iredell, Westmead Hospital and Westmead Institute for Medical Research

AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

Jun 7, 2018, 9:21pm UTC
https://www.businesswire.com/news/home/20180607005921/en/ > SAN DIEGO--(BUSINESS WIRE)--Jun 7, 2018--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a late-breaker poster presentation describing four case studies of patients suffering from severe Staphylococcus aureus ( S. aureus ) infections, who received treatment with AB-SA01, AmpliPhi’s investigational bacteriophage drug candidate. The presentation will be made at the American Society for Microbiology (ASM) Microbe 2018 annual meeting, being held June 7-11, 2018 in Atlanta. The abstract can be viewed here. > Poster Presentation: Title: AAR LB16 - Bacteriophages as adjuvant therapy for the treatment of severe staphylococcal sepsis Date and time: Friday, June 8, 2018, 11 a.m. - 1 p.m. EDT Session: 048 - FRIDAY - AAR Late-breakers Track: AAR Location: Exhibit and Poster Hall, Building B, Halls B2-B5, Georgia World Congress Center, Atlanta, Georgia Presenter: Dr. Jonathan Iredell, Westmead Hospital and Westmead Institute for Medical Research